GlassScriptPhysician profile
Amr Hegazi
NPI 1366443152
$10,721.95
in general payments reported to CMS, 2019-2025
80 companies · $3,026 in 2025
The $3,026 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,433 · 2020: $1,799 · 2021: $1,309 · 2022: $460 · 2023: $587 · 2024: $1,109 · 2025: $3,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,429 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,429.14 |
| Education | $292.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,064.86 | 2019-2025 | Darzalex, Erleada, Talvey |
| Astrazeneca Pharmaceuticals LP | $874.77 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $578.17 | 2019-2025 | |
| Genentech USA, INC. | $563.36 | 2019-2025 | Polivy, Tecentriq, Tecentriq Hybreza |
| E.R. Squibb & Sons, L.L.C. | $507.86 | 2019-2025 | Opdivo |
| Glaxosmithkline, LLC. | $464.94 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $358.22 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genzyme Corporation | $340.67 | 2019-2025 | |
| Amgen INC. | $317.78 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Abbvie INC. | $306.40 | 2019-2025 | |
| Pfizer INC. | $305.21 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $281.12 | 2019-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $264.89 | 2022-2025 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $252.43 | 2019-2025 | Iclusig, Vpriv |
| Daiichi Sankyo INC. | $245.82 | 2019-2025 | Enhertu, Injectafer |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amr Hegazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.